Semaglutide

SM2

Long-acting GLP-1 receptor agonist with 94% homology to native GLP-1. FDA-approved for T2D (Ozempic®, 2017), obesity (Wegovy®, 2021), and CV risk reduction (2024). Available as weekly injection or daily oral tablet.

>99%

Purity (HPLC)

Vials per Set

Dose Options

Select Your Dose

Each order includes 10 vials

Semaglutide 2mg × 10 vials

Code: SM2

Full Research Profile

Protocols, clinical evidence, interactions & more on Pep-Pedia